Long QT syndrome 3

Common Name(s)

Long QT syndrome 3

Congenital long QT syndrome is electrocardiographically characterized by a prolonged QT interval and polymorphic ventricular arrhythmias (torsade de pointes). These cardiac arrhythmias may result in recurrent syncopes, seizure, or sudden death ({4:Jongbloed et al., 1999}).
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Long QT syndrome 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Long QT syndrome 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Long QT syndrome 3" returned 17 free, full-text research articles on human participants. First 3 results:

A case of Long QT syndrome type 3 aggravated by beta-blockers and alleviated by mexiletine: the role of epinephrine provocation test.
 

Author(s): Junbeom Park, Sook Kyoung Kim, Hui-Nam Pak

Journal: Yonsei Med. J.. 2013 Mar;54(2):529-33.

 

Long QT syndrome (LQTs) is an uncommon genetic disease causing sudden cardiac death with Torsade de Pointes (TdP). The first line drug treatment has been known to be β-blocker. We encountered a 15-year-old female student with LQTs who had prolonged QTc and multiple episodes of syncope ...

Last Updated: 31 Jan 2013

Go To URL
Variants in the 3' untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner.
 

Author(s): Ahmad S Amin, John R Giudicessi, Anke J Tijsen, Anne M Spanjaart, Yolan J Reckman, Christine A Klemens, Michael W Tanck, Jamie D Kapplinger, Nynke Hofman, Moritz F Sinner, Martina Müller, Wino J Wijnen, Hanno L Tan, Connie R Bezzina, Esther E Creemers, Arthur A M Wilde, Michael J Ackerman, Yigal M Pinto

Journal: Eur. Heart J.. 2012 Mar;33(6):714-23.

 

Heterozygous mutations in KCNQ1 cause type 1 long QT syndrome (LQT1), a disease characterized by prolonged heart rate-corrected QT interval (QTc) and life-threatening arrhythmias. It is unknown why disease penetrance and expressivity is so variable between individuals hosting identical ...

Last Updated: 16 Mar 2012

Go To URL
Cardiomyocytes obtained from induced pluripotent stem cells with long-QT syndrome 3 recapitulate typical disease-specific features in vitro.
 

Author(s): Daniela Malan, Stephanie Friedrichs, Bernd K Fleischmann, Philipp Sasse

Journal: Circ. Res.. 2011 Sep;109(8):841-7.

 

Current approaches for the investigation of long-QT syndromes (LQTS) are mainly focused on identification of the mutation and its characterization in heterologous expression systems. However, it would be extremely helpful to be able to characterize the pathophysiological effects of ...

Last Updated: 30 Sep 2011

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Long QT syndrome 3" returned 0 free, full-text review articles on human participants.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Modifier Genes in Sudden Cardiac Death
 

Status: Not yet recruiting

Condition Summary: Brugada Syndrome; Long QT Syndrome 3

 

Last Updated: 12 Dec 2013

Go to URL
Efficacy Study of Sodium Channel Blocker in LQT3 Patients
 

Status: Recruiting

Condition Summary: Long QT Syndrome

 

Last Updated: 11 Dec 2013

Go to URL
Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine
 

Status: Recruiting

Condition Summary: Long QT Syndrome Type 3

 

Last Updated: 12 Nov 2012

Go to URL